Taiwania Capital Management Corporation

Taiwania Capital, founded in 2017 and based in Taipei, Taiwan, is a venture capital firm focused on fostering economic growth in Taiwan through strategic partnerships with global companies. The firm manages multiple funds, including those that target early-stage investments in various sectors such as enterprise software, artificial intelligence, autonomous systems, and information technology. Additionally, Taiwania Capital has dedicated funds for specific regions, investing in markets like the United States, Japan, Israel, and Eastern and Northern Europe. Its investment strategy encompasses a wide range of industries, including healthcare, biotechnology, and consumer products, aiming to support innovation and development in these fields.

Michael Huang

Managing Partner

David Weng

CEO

Past deals in Cayman Islands

Xgene Pharmaceutical

Series B in 2022
Xgene Pharmaceutical Inc. is a late-clinical stage pharmaceutical company established in 2015, based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Utilizing proprietary linker technology, Xgene creates novel, multimodal conjugated molecules that enhance the efficacy and tolerability of pain medications. The company's current programs are dedicated to addressing unmet needs in neurological disorders, making significant strides in the development of innovative treatments for these conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.